ArticleBiomaterials2013
Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.ACS nano · 2020Pooled it
- Radiolabelled ZnO, Iron Oxide-Based, and Gold Nanoparticles for Cancer Therapy: Synthesis, Surface Engineering, and Radiolabelling Strategies.International journal of molecular sciences · 2026Review
- Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics.Nuclear medicine and molecular imaging · 2025Review
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Magnetic Particle Imaging-Guided Hyperthermia for Precise Treatment of Cancer: Review, Challenges, and Prospects.Molecular imaging and biology · 2023Review
- Approaches to Nanoparticle Labeling: A Review of Fluorescent, Radiological, and Metallic Techniques.Environment & health (Washington, D.C.) · 2023Review
- Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance.Journal of nanobiotechnology · 2023Article
- Iron-Gold Nanoflowers: A Promising Tool for Multimodal Imaging and Hyperthermia Therapy.Pharmaceutics · 2022Article
- Design of Magnetic Nanoplatforms for Cancer Theranostics.Biosensors · 2022Review
- Amalgamation of Nanoparticles within Drug Carriers: A Synergistic Approach or a Futile Attempt?Pharmaceutical nanotechnology · 2022Review
- Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery.ACS omega · 2021Article
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting.Frontiers in pharmacology · 2021Review
- Gold-based Inorganic Nanohybrids for Nanomedicine Applications.Theranostics · 2020Review
- Radiolabeled PET/MRI Nanoparticles for Tumor Imaging.Journal of clinical medicine · 2019Review
- Advances in Magnetic Noble Metal/Iron-Based Oxide Hybrid Nanoparticles as Biomedical Devices.Bioengineering (Basel, Switzerland) · 2019Review
- Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.Journal of nanobiotechnology · 2019Review
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- Nanoheterostructures (NHS) and Their Applications in Nanomedicine: Focusing on In Vivo Studies.Materials (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A highly monodispersed hetero-nanostructure with two different functional nanomaterials (gold (Au) and iron oxide (Fe(3)O(4,) IO)) within one structure was successfully developed as Affibody based trimodality nanoprobe (positron emission tomography, PET; optical imaging; and magnetic resonance imaging, MRI) for imaging of epidermal growth factor receptor (EGFR) positive tumors. Unlike other regular nanostructures with a single component, the Au-IO hetero-nanostructures (Au-IONPs) with unique chemical and physical properties have capability to combine several imaging modalities together to provide complementary information. The IO component within hetero-nanostructures serve as a T(2) reporter for MRI; and gold component serve as both optical and PET reporters. Moreover, such hetero-nanoprobes could provide a robust nano-platform for surface-specific modification with both targeting molecules (anti-EGFR Affibody protein) and PET imaging reporters (radiometal (64)Cu chelators) in highly efficient and reliable manner. In vitro and in vivo study showed that the resultant nanoprobe provided high specificity, sensitivity, and excellent tumor contrast for both PET and MRI imaging in the human EGFR-expressing cells and tumors. Our study data also highlighted the EGFR targeting efficiency of hetero-nanoparticles and the feasibility for their further theranostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.